Iranian Registry of Crohn's and Colitis: study profile of first nation-wide inflammatory bowel disease registry in Middle East.
Inflammatory bowel disease
Iran
Registry
Journal
Intestinal research
ISSN: 1598-9100
Titre abrégé: Intest Res
Pays: Korea (South)
ID NLM: 101572802
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
03
12
2018
accepted:
08
02
2019
pubmed:
23
4
2019
medline:
23
4
2019
entrez:
23
4
2019
Statut:
ppublish
Résumé
A recent study revealed increasing incidence and prevalence of inflammatory bowel disease (IBD) in Iran. The Iranian Registry of Crohn's and Colitis (IRCC) was designed recently to answer the needs. We reported the design, methods of data collection, and aims of IRCC in this paper. IRCC is a multicenter prospective registry, which is established with collaboration of more than 100 gastroenterologists from different provinces of Iran. Minimum data set for IRCC was defined according to an international consensus on standard set of outcomes for IBD. A pilot feasibility study was performed on 553 IBD patients with a web-based questionnaire. The reliability of questionnaire evaluated by Cronbach's α. All sections of questionnaire had Cronbach's α of more than 0.6. In pilot study, 312 of participants (56.4%) were male and mean age was 38 years (standard deviation=12.8) and 378 patients (68.35%) had ulcerative colitis, 303 subjects (54,7%) had college education and 358 patients (64.74%) were of Fars ethnicity. We found that 68 (12.3%), 44 (7.9%), 13 (2.3%) of participants were smokers, hookah and opium users, respectively. History of appendectomy was reported in 58 of patients (10.48%). The most common medication was 5-aminosalicylate (94.39%). To the best of our knowledge, IRCC is the first national IBD registry in the Middle East and could become a reliable infrastructure for national and international research on IBD. IRCC will improve the quality of care of IBD patients and provide national information for policy makers to better plan for controlling IBD in Iran.
Sections du résumé
BACKGROUND/AIMS
OBJECTIVE
A recent study revealed increasing incidence and prevalence of inflammatory bowel disease (IBD) in Iran. The Iranian Registry of Crohn's and Colitis (IRCC) was designed recently to answer the needs. We reported the design, methods of data collection, and aims of IRCC in this paper.
METHODS
METHODS
IRCC is a multicenter prospective registry, which is established with collaboration of more than 100 gastroenterologists from different provinces of Iran. Minimum data set for IRCC was defined according to an international consensus on standard set of outcomes for IBD. A pilot feasibility study was performed on 553 IBD patients with a web-based questionnaire. The reliability of questionnaire evaluated by Cronbach's α.
RESULTS
RESULTS
All sections of questionnaire had Cronbach's α of more than 0.6. In pilot study, 312 of participants (56.4%) were male and mean age was 38 years (standard deviation=12.8) and 378 patients (68.35%) had ulcerative colitis, 303 subjects (54,7%) had college education and 358 patients (64.74%) were of Fars ethnicity. We found that 68 (12.3%), 44 (7.9%), 13 (2.3%) of participants were smokers, hookah and opium users, respectively. History of appendectomy was reported in 58 of patients (10.48%). The most common medication was 5-aminosalicylate (94.39%).
CONCLUSIONS
CONCLUSIONS
To the best of our knowledge, IRCC is the first national IBD registry in the Middle East and could become a reliable infrastructure for national and international research on IBD. IRCC will improve the quality of care of IBD patients and provide national information for policy makers to better plan for controlling IBD in Iran.
Identifiants
pubmed: 31006228
pii: ir.2018.00157
doi: 10.5217/ir.2018.00157
pmc: PMC6667360
doi:
Types de publication
Journal Article
Langues
eng
Pagination
330-339Subventions
Organisme : Manitoba Labour and Immigration
Références
Arthritis Rheum. 2003 Apr 15;49(2):156-63
pubmed: 12687505
Gut. 2004 Jun;53(6):843-8
pubmed: 15138211
Curr Opin Gastroenterol. 2005 Jul;21(4):408-13
pubmed: 15930979
Postgrad Med J. 2006 May;82(967):332-7
pubmed: 16679472
Inflamm Bowel Dis. 2007 Mar;13(3):254-61
pubmed: 17206702
Eur J Vasc Endovasc Surg. 2007 Sep;34(3):253-6
pubmed: 17689818
Am J Gastroenterol. 2009 Jul;104(7):1754-63
pubmed: 19455122
Gastroenterology. 2010 Sep;139(3):779-87, 787.e1
pubmed: 20546736
J Gastroenterol Hepatol. 2012 Aug;27(8):1266-80
pubmed: 22497584
J Gastroenterol Hepatol. 2013 Jul;28(7):1148-53
pubmed: 23432198
Inflamm Bowel Dis. 2013 Aug;19(9):1839-45
pubmed: 23669403
Gut. 2014 Jul;63(7):1092-102
pubmed: 24107590
Middle East J Dig Dis. 2012 Apr;4(2):97-101
pubmed: 24829641
BMC Gastroenterol. 2014 Aug 09;14:140
pubmed: 25108544
Intest Res. 2014 Jul;12(3):173-5
pubmed: 25349589
Intest Res. 2015 Jul;13(3):208-12
pubmed: 26130994
Nat Genet. 2015 Sep;47(9):979-986
pubmed: 26192919
Arch Iran Med. 2016 Jan;19(1):2-15
pubmed: 26702742
Inflamm Bowel Dis. 2016 Aug;22(8):1954-60
pubmed: 27416041
Dig Dis Sci. 2016 Nov;61(11):3236-3245
pubmed: 27619390
J Clin Gastroenterol. 2016 Nov/Dec;50(10):803-818
pubmed: 27741097
Inflamm Bowel Dis. 2017 Jul;23(7):1187-1194
pubmed: 28410340
Inflamm Bowel Dis. 2017 Nov;23(11):1941-1949
pubmed: 28991858
Lancet. 2018 Dec 23;390(10114):2769-2778
pubmed: 29050646
J Crohns Colitis. 2018 Mar 28;12(4):408-418
pubmed: 29216349
Arch Iran Med. 2017 Nov 01;20(11):696-703
pubmed: 29480735
Adv Biomed Res. 2018 Mar 27;7:45
pubmed: 29657930